Medical Weight Loss Therapy - GLP-1 - New York

SEMAGLUTIDE is a peptide that imitates the hormone glucagon-like peptide 1 (GLP-1), which targets the brain's appetite-regulating area and controls food intake. This hormone is released after eating and plays a vital role in managing blood sugar levels. It boosts insulin production and slows down digestion. In 2017, the FDA approved Semaglutide for treating type 2 diabetes under the brand name Ozempic, and it has now gained FDA approval in 2021 under the brand name Wegovy for weight loss. It is administered as a once-weekly injection under the skin. The most common side effects include mild nausea, vomiting, diarrhea, stomach pain, and constipation, which usually improve over time as the body adjusts to the medication. In clinical trials, participants who used semaglutide for weight loss experienced an average weight loss of around 15% of their body weight (However, individual results may vary.)

 TIRZEPATIDE is a groundbreaking weight loss medication that has received dual FDA approval. It stands out from other treatments as it imitates two important hormones, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1, instead of just one. This unique mechanism of action allows tirzepatide to achieve greater weight loss compared to medications that only target GLP-1. By activating both hormones, tirzepatide effectively stimulates insulin secretion and slows down digestion, resulting in a feeling of fullness and reduced hunger.   In 2022, the FDA approved tirzepatide for treating type 2 diabetes under the brand name Mounjaro, and it has now gained FDA approval in 2023 under the brand name Zepound for weight loss.

Clinical trials have shown that higher doses of tirzepatide can lead to a significant weight loss of around 20%. The medication is administered as a once-weekly injection, and the most common side effects are related to gastrointestinal disturbances such as nausea, vomiting, and diarrhea. These side effects typically improve as the body adjusts to the medication.